Paul Klekotka Selected Research

Interleukin-17 Receptors

1/2020	Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
6/2015	Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis.
3/2015	Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis.
11/2014	Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Paul Klekotka Research Topics

Disease

12	COVID-19 01/2022 - 01/2021
9	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2020 - 07/2012
2	Atopic Dermatitis (Atopic Eczema) 10/2022 - 09/2020
2	Disease Progression 12/2021 - 10/2021
2	Infections 10/2021 - 01/2021
2	Crohn Disease (Crohn's Disease) 07/2017 - 11/2016
1	Urinary Tract Infections (Urinary Tract Infection) 01/2021
1	Immediate Hypersensitivity 01/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Ulcerative Colitis 01/2020
1	Hemorrhage 01/2020
1	Inflammation (Inflammations) 12/2016
1	Chronic Obstructive Pulmonary Disease (COPD) 07/2016
1	Lung Diseases (Lung Disease) 07/2016
1	Asthma (Bronchial Asthma) 12/2015
1	Body Weight (Weight, Body) 10/2015
1	Candidiasis (Moniliasis) 10/2015
1	Neutropenia 10/2015
1	Psoriatic Arthritis 03/2015
1	Erythema 07/2012

Drug/Important Bio-Agent (IBA)

10	bamlanivimabIBA 01/2022 - 01/2021
10	Monoclonal AntibodiesIBA 01/2022 - 10/2015
7	brodalumabIBA 01/2020 - 11/2014
4	Interleukin-17 ReceptorsIBA 01/2020 - 11/2014
3	bamlanivimab and etesevimab drug combinationIBA 01/2022 - 01/2021
3	etesevimabIBA 01/2022 - 01/2021
3	Interleukin-17 (Interleukin 17)IBA 01/2020 - 01/2013
3	CytokinesIBA 07/2017 - 01/2013
2	AntigensIBA 01/2022 - 12/2021
2	remdesivirIBA 01/2022 - 11/2021
2	Antiviral Agents (Antivirals)IBA 12/2021 - 09/2021
2	Neutralizing AntibodiesIBA 01/2021 - 01/2021
2	Interleukin-23 (Interleukin 23)IBA 01/2020 - 07/2017
2	Ustekinumab (CNTO 1275)FDA Link 01/2020 - 10/2015
1	Interleukin-33IBA 10/2022
1	RNA (Ribonucleic Acid)IBA 12/2021
1	Nucleic AcidsIBA 12/2021
1	VaccinesIBA 10/2021
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2021
1	Pharmaceutical PreparationsIBA 09/2020
1	Immunoglobulin A (IgA)IBA 09/2020
1	mirikizumabIBA 01/2020
1	Tumor Necrosis Factor InhibitorsIBA 07/2017
1	MEDI2070IBA 07/2017
1	GoldIBA 07/2016
1	Bronchodilator Agents (Bronchodilators)IBA 12/2015
1	Immunoglobulin E (IgE)IBA 12/2015
1	Indicators and Reagents (Reagents)IBA 12/2015
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2015
1	Biomarkers (Surrogate Marker)IBA 12/2015
1	Biological ProductsIBA 03/2015
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2013
1	Etanercept (Enbrel)FDA Link 07/2012

Therapy/Procedure

6	Therapeutics 12/2021 - 03/2015
2	Intravenous Infusions 10/2021 - 01/2021
1	Retreatment 01/2020
1	Subcutaneous Injections 07/2012
1	Biological Therapy 07/2012